Af­ter pan­dem­ic de­lay and a South Ko­re­an deal, Boston-area biotech rais­es Se­ries B with sights on IPO

Two years af­ter snar­ing a $45 mil­lion Se­ries A from a cou­ple of top-flight in­vestors, Neu­ro­gas­trx was fi­nal­ly ready to put its lead mol­e­cule in­to the clin­i­cal tri­als when the world shut down in March 2020.

The small, GI-fo­cused biotech’s plans were, like many that spring, de­railed.

“A lot of in­sti­tu­tions were not al­low­ing pa­tients in­to hos­pi­tals or test­ing cen­ters,” CEO Jim O’Mara said. “That de­layed us for months.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER